Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights
Provided By GlobeNewswire
Last update: Nov 13, 2024
First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity
Oral small molecule amylin receptor agonist development candidate
expected to be selected by the end of 2024
